Literature DB >> 15372598

Development of Parkinson's disease in patients with blepharospasm.

Federico Micheli1, María Clara Scorticati, Silvia Folgar, Emilia Gatto.   

Abstract

The liability to develop parkinsonian symptoms was evaluated in 105 outpatients with idiopathic blepharospasm (IBS; 54 cases) or IBS associated to oromandibular dystonia (Meige's syndrome; 51 cases) mean age 70.3 +/- 9.6 years, and compared with an age- and sex-matched population. Eleven patients developed Parkinson's disease in the blepharospasm group, whereas only 2 of 105 patients were affected in the control group. Our results suggest that patients with IBS either isolated or associated with oromandibular dystonia are more prone to develop parkinsonian symptoms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15372598     DOI: 10.1002/mds.20084

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  4 in total

1.  Influence of coffee drinking and cigarette smoking on the risk of primary late onset blepharospasm: evidence from a multicentre case control study.

Authors:  G Defazio; D Martino; G Abbruzzese; P Girlanda; M Tinazzi; G Fabbrini; C Colosimo; M S Aniello; L Avanzino; M Buccafusca; G Majorana; C Trompetto; P Livrea; A Berardelli
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-06-19       Impact factor: 10.154

2.  Dementia with lewy bodies in meige syndrome.

Authors:  Lap Kei Chan; Ho Yin Ho; Chi Shing Yu
Journal:  Innov Clin Neurosci       Date:  2012-07

3.  Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease.

Authors:  Qian-Ya Fan; Xiao-Dong Zhang; Ze-Di Hu; Shi-Shi Huang; Shi-Guo Zhu; Cai-Ping Chen; Xiong Zhang; Jian-Yong Wang
Journal:  Front Neurol       Date:  2022-09-30       Impact factor: 4.086

Review 4.  Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins.

Authors:  Travis J W Hassell; David Charles
Journal:  Toxins (Basel)       Date:  2020-04-22       Impact factor: 4.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.